Your browser doesn't support javascript.
loading
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Pepper, Andrea G S; Zucchetto, Antonella; Norris, Kevin; Tissino, Erika; Polesel, Jerry; Soe, Zarni; Allsup, David; Hockaday, Anna; Ow, Pei Loo; Hillmen, Peter; Rawstron, Andrew; Catovsky, Daniel; Bulian, Pietro; Bomben, Riccardo; Baird, Duncan M; Fegan, Christopher D; Gattei, Valter; Pepper, Chris.
Afiliação
  • Pepper AGS; Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.
  • Zucchetto A; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Norris K; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom.
  • Tissino E; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Polesel J; Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Soe Z; Leeds Teaching Hospital Trust, Leeds, United Kingdom.
  • Allsup D; Hull York Medical School, University of Hull, Hull, United Kingdom.
  • Hockaday A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Ow PL; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Hillmen P; Section of Experimental Haematology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
  • Rawstron A; Section of Experimental Haematology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
  • Catovsky D; Institute of Cancer Research, Sutton, United Kingdom.
  • Bulian P; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Bomben R; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Baird DM; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom.
  • Fegan CD; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom.
  • Gattei V; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Pepper C; Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom. c.pepper@bsms.ac.uk.
Leukemia ; 36(1): 271-274, 2022 01.
Article em En | MEDLINE | ID: mdl-34148055
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Região Variável de Imunoglobulina / Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Cadeias Pesadas de Imunoglobulinas / Integrina alfa4 / Homeostase do Telômero / Mutação Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Região Variável de Imunoglobulina / Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Cadeias Pesadas de Imunoglobulinas / Integrina alfa4 / Homeostase do Telômero / Mutação Idioma: En Ano de publicação: 2022 Tipo de documento: Article